Compare Stocks: DMRA, GRFS, IOVA, and ERAS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$20.23 -4.9%	$27.58	$3.50 ▼ $38.33	$1.31B	1.43	793,275 shs	354,631 shs
ERAS Erasca	$14.58 -0.5%	$16.94	$2.11 ▼ $24.28	$5.13B	0.61	4.48 million shs	3.69 million shs
GRFS Grifols	$7.30 -0.1%	$7.73	$6.96 ▼ $10.23	$4.98B	0.7	618,932 shs	623,126 shs
IOVA Iovance Biotherapeutics	$14.23 -4.0%	$8.16	$1.76 ▼ $15.30	$6.71B	0.75	17.77 million shs	15.95 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	+3.00%	+4.11%	-24.49%	-29.02%	+472.04%
ERAS Erasca	+3.17%	+5.16%	-18.01%	-20.63%	+572.48%
GRFS Grifols	+0.14%	+1.53%	-5.31%	+2.09%	-26.61%
IOVA Iovance Biotherapeutics	+2.56%	+45.44%	+81.40%	+243.85%	+582.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$20.23 -4.9%	$27.58	$3.50 ▼ $38.33	$1.31B	1.43	793,275 shs	354,631 shs
ERAS Erasca	$14.58 -0.5%	$16.94	$2.11 ▼ $24.28	$5.13B	0.61	4.48 million shs	3.69 million shs
GRFS Grifols	$7.30 -0.1%	$7.73	$6.96 ▼ $10.23	$4.98B	0.7	618,932 shs	623,126 shs
IOVA Iovance Biotherapeutics	$14.23 -4.0%	$8.16	$1.76 ▼ $15.30	$6.71B	0.75	17.77 million shs	15.95 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	+3.00%	+4.11%	-24.49%	-29.02%	+472.04%
ERAS Erasca	+3.17%	+5.16%	-18.01%	-20.63%	+572.48%
GRFS Grifols	+0.14%	+1.53%	-5.31%	+2.09%	-26.61%
IOVA Iovance Biotherapeutics	+2.56%	+45.44%	+81.40%	+243.85%	+582.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$46.50	129.86% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	51.52% Upside
GRFS Grifols	1.67	Reduce	$10.00	36.99% Upside
IOVA Iovance Biotherapeutics	2.67	Moderate Buy	$12.40	-12.86% Downside

Current Analyst Ratings Breakdown

Latest DMRA, GRFS, IOVA, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$14.00 ➝ $18.00
9/29/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/29/2026	DMRA Damora Therapeutics, Inc. Common Stock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
9/29/2026	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $20.00
9/25/2026	DMRA Damora Therapeutics, Inc. Common Stock	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
9/24/2026	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$15.00
9/24/2026	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$15.00
9/17/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$13.00 ➝ $15.00
9/14/2026	DMRA Damora Therapeutics, Inc. Common Stock	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	DMRA Damora Therapeutics, Inc. Common Stock	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
GRFS Grifols	$8.51B	0.58	$1.41 per share	5.16	$12.64 per share	0.58
IOVA Iovance Biotherapeutics	$263.50M	24.46	N/A	N/A	$1.76 per share	8.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	38.42	5.45	0.27	5.54%	6.21%	2.39%	11/10/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)

Latest DMRA, GRFS, IOVA, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.09	1.23%	N/A	47.37%	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
ERAS Erasca	N/A	8.29	8.29
GRFS Grifols	1.10	2.37	0.81
IOVA Iovance Biotherapeutics	N/A	4.34	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
ERAS Erasca	67.78%
GRFS Grifols	N/A
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
ERAS Erasca	14.20%
GRFS Grifols	0.19%
IOVA Iovance Biotherapeutics	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
ERAS Erasca	103	349.76 million	300.10 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable

DMRA, GRFS, IOVA, and ERAS Headlines

Recent News About These Companies

Iovance Biotherapeutics Names Noah Berkowitz CMO

October 1 at 9:05 AM | rttnews.com

IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook

October 1 at 9:05 AM | finance.yahoo.com

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

October 1 at 7:00 AM | globenewswire.com

HC Wainwright Brokers Increase Earnings Estimates for IOVA

October 1 at 6:12 AM | americanbankingnews.com

HC Wainwright Brokers Boost Earnings Estimates for IOVA

October 1 at 6:11 AM | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Iovance Biotherapeutics (NASDAQ:IOVA) Stock

October 1 at 1:54 AM | americanbankingnews.com

Iovance Biotherapeutics Shares Jump After 2026 Revenue Guidance Raised

September 30 at 12:38 AM | marketscreener.comM

Iovance Biotherapeutics (IOVA) Receives a Buy from TD Cowen

September 30 at 2:36 PM | theglobeandmail.com

IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026

September 30 at 11:26 AM | zacks.com

Iovance Biotherapeutics (NASDAQ:IOVA) Given New $18.00 Price Target at Wells Fargo & Company

September 30 at 10:59 AM | marketbeat.com

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

September 30 at 8:16 AM | zacks.com

Head to Head Comparison: ADMA Biologics (NASDAQ:ADMA) and Iovance Biotherapeutics (NASDAQ:IOVA)

September 30 at 2:15 AM | americanbankingnews.com

Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth

September 29 at 12:00 AM | barrons.com

Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%

September 29 at 12:00 AM | finance.yahoo.com

Iovance Biotherapeutics Stock Rises 33% After Raising FY26 Total Revenue Outlook

September 29 at 6:59 PM | rttnews.com

Stocks making the biggest moves midday: Carnival, Fair Isaac, Bloom Energy, Iovance Biotherapeutics & more

September 29 at 6:59 PM | cnbc.com

Iovance Biotherapeutics Raises 2026 Revenue Guidance On Strong Amtagvi Demand; Stock Up

September 29 at 6:59 PM | rttnews.com

Iovance shares jump in premarket as raised outlook clears consensus views

September 29 at 6:59 PM | au.finance.yahoo.com

Iovance Biotherapeutics (IOVA) Stock Rises on Higher Full-Year Outlook

September 29 at 6:59 PM | coincentral.comC

Iovance Biotherapeutics Stock Gains After Raising FY Revenue Guidance on Demand for Melanoma Treatments

September 29 at 6:59 PM | marketwatch.com

Update: Iovance Biotherapeutics Shares Jump After 2026 Revenue Guidance Raised

September 29 at 6:59 PM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, GRFS, IOVA, and ERAS Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$20.23 -1.05 (-4.93%)

As of 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Erasca NASDAQ:ERAS

$14.58 -0.08 (-0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$14.56 -0.02 (-0.15%)

As of 07:50 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Grifols NASDAQ:GRFS

$7.30 -0.01 (-0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$7.31 +0.01 (+0.14%)

As of 04:10 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Iovance Biotherapeutics NASDAQ:IOVA

$14.23 -0.59 (-3.98%)

Closing price 04:00 PM Eastern

Extended Trading

$14.22 -0.01 (-0.04%)

As of 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, GRFS, IOVA, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, GRFS, IOVA, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, GRFS, IOVA, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, GRFS, IOVA, and ERAS Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, GRFS, IOVA, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, GRFS, IOVA, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, GRFS, IOVA, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, GRFS, IOVA, and ERAS Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools